 FRAMINGHAM, MA ACCESSWIRE January 14, 2021 Xenetic Biosciences, Inc. NASDAQ:XBIO Xenetic or the Company, a biopharmaceutical company focused on advancing XCARTTM, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET. A high-definition, video webcast will be available at the time of the Companys presentation to those registered to attend the event. 